@shemed_uk is the first female-focused GLP-1 company in the UK with a mission to close the women’s health research gap by examining the potential of these medications to address specific women’s health conditions, including PMOS, endometriosis, menopause symptoms, and other areas that remain under-researched.
GLP-1 medications are transforming how we think about chronic disease, yet up to 60% of patients quit within the first year. In her chat @sxswlondon, eMed CEO Linda Yaccarino makes the case that GLP-1s are not a weight loss story, they’re a preventative care story.
Tap the link in bio to learn more about how GLP-1 drugs have transformed medicine
